Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Appointed director

Inmune Bio, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
12/03/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INMUNE BIO PRESS RELEASE DATED DECEMBER 2, 2019"
11/29/2019 8-K Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce...
Docs: "INmune Bio’ s CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Alzheimer’ s drug development."
11/27/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/27/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/27/2019 4 Moss David J (CFO, Treasurer & Secretary) has filed a Form 4 on Inmune Bio, Inc.
Txns: Granted 300,000 options @ $3.91, valued at $1.2M
11/27/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/27/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/27/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/27/2019 4 Baracchini Edgardo Jr (Director) has filed a Form 4 on Inmune Bio, Inc.
Txns: Granted 108,000 options @ $3.91, valued at $422.3k
11/20/2019 8-K Quarterly results
11/12/2019 8-K Quarterly results
11/08/2019 10-Q Quarterly Report for the period ended September 30, 2019
10/21/2019 8-K Quarterly results
10/08/2019 8-K Quarterly results
09/23/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Session 3: Therapeutics: State of the Field Presentation Title: A Biomarker-Directed Approach to Targeting Inflammation in Alzheimer’ s Patients Time and Date: 5:10 PM – 5:30 PM, Sept. 25 Location: Hyatt Regency Sydney, Australia"
09/18/2019 8-K Quarterly results
09/12/2019 4 Lowdell Mark William (Chief Scientific Officer) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 2,918 shares @ $6.2298, valued at $18.2k
09/12/2019 8-K Quarterly results
09/12/2019 8-K Quarterly results
09/09/2019 8-K Quarterly results
09/04/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference"
08/27/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Investor Fact Sheet"
08/22/2019 4 Juda Scott (Director) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 2,500 shares @ $6, valued at $15k
Bought 2,500 shares @ $6, valued at $15k
08/21/2019 4 Moss David J (CFO, Treasurer & Secretary) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 77 shares @ $5.65, valued at $435.1
Bought 239 shares @ $5.65, valued at $1.4k
Bought 2,000 shares @ $5.65, valued at $11.3k
Bought 72 shares @ $5.65, valued at $406.8
Bought 236 shares @ $5.65, valued at $1.3k
Bought 376 shares @ $5.65, valued at $2.1k
08/21/2019 4 Tesi Raymond Joseph (President & CEO) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 100 shares @ $5.96, valued at $596
Bought 100 shares @ $5.9239, valued at $592.4
Bought 1,000 shares @ $6.0308, valued at $6k
08/16/2019 3 Form 3 - Initial statement of beneficial ownership of securities:
08/15/2019 8-K Quarterly results
08/13/2019 8-K Quarterly results
08/12/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/09/2019 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/09/2019 8-K Quarterly results
08/09/2019 10-Q Quarterly Report for the period ended June 30, 2019
08/07/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer"
08/01/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit La Jolla, CA. – Aug. 1, 2019 – INmune Bio, Inc. , an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that RJ Tesi, M.D., co-founder and CEO, will present at the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit, taking place in Boston from Aug. 5 through Aug. 9. “We are committed to helping treatment-resistant patients by advancing the clinical development of combination therapies and other effective cancer treatments,” said Dr. Tesi. “I am delighted to have the chance to present with some of the most prominent leaders in the immuno-oncology community.” Below is a schedule ..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy